DXRX logo
Lab Talks & Webinars

A new perspective on HER2 testing – Evolving the lab practices to match clinical advances​

21 May 2024

This non-promotional event is organized and funded by AstraZeneca and is intended for healthcare professionals only. Z4-62772. DOP: March 2024. Any use and distribution of the information contained in this document must be assessed and approved in accordance with regional/local approval processes to ensure compliance with applicable local laws, regulations, codes and AZ policies.

AZ Logo

Our latest Lab Talk discusses the new perspective emerging on the HER2 testing landscape and the need for consistent and reliable scoring to optimize performance in the diagnostic process to ensure eligible patients receive targeted therapies. 

Date: 5th June 2024

Time: 2.30pm GMT

This session will analyze the clinical utility of HER2 testing, technical considerations (both pre-analytical and analytical), scoring reproducibility and include a Q&A session with Prof. Dr Abeer Shaaban MBBCh, MSc, PhD, FRC Path​.

Can't make the live session? Register to receive the recording!
Register

Speaker name: Prof. Dr Abeer Shaaban MBBCh, MSc, PhD, FRCPath​

Prof. Dr Abeer Shaaban

Prof. Dr Shaaban is a Consultant Pathologist at Queen Elizabeth Hospital Birmingham and Professor of Cancer and Genomic Sciences, University of Birmingham, UK. As the CRUK Birmingham Centre Pathologist, she supported translational and digital pathology & multiplex immunofluorescence studies.

She has led a number of research studies and contributed to breast cancer trials as co-investigator, member of a Trial Management Group and as a central pathology reviewer. Her research interest includes profiling tumour microenvironment, tissue microarrays, predictors of response/resistance to therapies and ethnic differences in cancer.

She was member of the NCRI Breast CSG for two terms and acted as chair of the NCRI Breast CSG Translational Subgroup for 5 years. The subgroup produced several landmark publications including guidance on improving the turnaround of HER2 testing, manufacture and reporting of tissue microarrays and handling of neoadjuvant chemotherapy specimens.

Prof. Dr Shaaban published over 150 peer reviewed papers and contributed a number of book chapters including in the WHO Blue Book for Breast tumours 2019 and the International Collaboration on Cancer Reporting (ICCR)DCIS dataset 2021. She co-edited a textbook of molecular pathology entitled “Molecular pathology for the practising surgical pathologist and cytopathologists”. She lectured on a number of UK and international courses/conferences including San Antonio Breast Cancer Symposium, BDIAP, ESSO, EBBC, Pathological Society of Great Britain and Ireland meetings and other. Prof Shaaban organises an annual multidisciplinary breast pathology update course http://birminghambreastpathology.org/bbpuc-2021.

Prof. Dr Shaaban led the NCRI Cellular and Molecular Pathology initiative (CM-PATH) Workstream 2 (Clinical Trials). She served as member of the International Committee of the Royal College of Pathologists, member of the Scientific Advisory Board of Breast Cancer Now and is Breast Screening Advisor for Public Health England.

This event is sponsored by AstraZeneca. This content is intended for healthcare professionals only. Z4-62772. Any use and distribution of the information contained in this document must be assessed and approved in accordance with regional/local approval processes to ensure compliance with applicable local laws, regulations, codes and AZ policies.